News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Crucell N.V. (CRXL) And DSM Biologics Announce PER.C6 Licensing Agreement With Merus For Production Of Monoclonal Antibody Combinations


10/19/2005 5:11:43 PM

Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) and allied contract manufacturer DSM Biologics announced today that Crucell and Merus B.V. have signed a PER.C6(r) research license agreement. This license agreement allows Merus to use the PER.C6(r) cell line for the further development of its Oligoclonics(tm) technology and related products.

Read at Prime Zone

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES